All articles tagged with #eli lilly
Originally Published 5 days ago — by statnews.com
Eli Lilly's drug Zepbound, when combined with its immunology therapy Taltz, showed promise in reducing symptoms of psoriatic arthritis in obese patients, suggesting potential new uses for the weight loss drug, though its impact on prescribing patterns remains uncertain.
Originally Published 6 days ago — by Yahoo Finance
Eli Lilly is in advanced negotiations to acquire Ventyx Biosciences for over $1 billion, which would expand Lilly's portfolio to include treatments for inflammatory bowel diseases and other conditions, with an announcement expected soon.
Originally Published 8 days ago — by CNBC
Eli Lilly shares are declining, possibly due to specific company or sector factors, while oil and financial stocks are experiencing a rally, reflecting mixed market movements on January 5, 2023.
Originally Published 12 days ago — by AL.com
Huntsville experienced a significant economic boom in 2025 with major investments like Eli Lilly's $6 billion pharmaceutical facility, the relocation of U.S. Space Command headquarters, and expansions in retail, arts, and technology sectors, positioning it as Alabama's top economic growth area.
Originally Published 16 days ago — by AL.com
Huntsville's success in attracting Eli Lilly's new pharma plant highlights its growing economic strength and ability to win major projects, surpassing Birmingham, which struggles with translating research into commercial products. The article emphasizes the need for Birmingham to focus on effective economic development and regional collaboration, drawing lessons from Alabama's successful auto industry growth and past achievements like the Mercedes-Benz project.
Originally Published 17 days ago — by The Motley Fool
The article highlights three top growth stocks to buy now: MercadoLibre, a leading Latin American e-commerce and fintech company; Eli Lilly, a healthcare giant with strong obesity and diabetes treatments; and Alphabet, Google's parent company, with impressive AI and cloud computing growth. These companies offer significant long-term growth potential due to their innovative industries and strong financials.
Originally Published 21 days ago — by TipRanks
Eli Lilly's stock declined after its rival Novo Nordisk received U.S. approval for its obesity medication, impacting investor sentiment in the pharmaceutical sector.
Originally Published 26 days ago — by CNBC
The article argues that Eli Lilly shares should be valued higher and discusses expectations and wishlist items for Nike's upcoming earnings report, providing insights into investment opportunities and market analysis.
Originally Published 28 days ago — by CNBC
By 2026, two new oral obesity pills from Novo Nordisk and Eli Lilly are expected to hit the U.S. market, offering a more convenient alternative to injections and potentially capturing a significant share of the growing weight loss drug market, with prices expected to be lower than current injectable options.
Originally Published 1 month ago — by CNBC
Eli Lilly has reduced the cash prices of its Zepbound weight loss drug vials on its direct-to-consumer platform, making the medication more accessible amid industry price cuts and government efforts to lower drug costs. Starting at $299 per month for the initial dose, the prices are now more affordable compared to the previous $349, aiming to improve access for patients facing high list prices and limited insurance coverage.
Originally Published 2 months ago — by Investor's Business Daily
The stock market experienced a positive session with the Dow Jones hitting a record close and futures rising slightly overnight. Several stocks like Eli Lilly and Palantir are in buy zones, while AI-related stocks faced declines. The market shows signs of a healthy rally with some volatility, and investors are advised to stay alert for actionable stocks and maintain their strategies.
Originally Published 2 months ago — by Barron's
Eli Lilly's stock reached a new high after a positive analyst upgrade and a deal with the U.S. government to lower drug prices, which is expected to boost obesity drug adoption and future drug launches, despite some concerns over valuation and competition.
Originally Published 2 months ago — by TipRanks
Eli Lilly's stock (LLY) was upgraded following news that obesity drugs will now be covered by Medicare, potentially boosting the company's prospects in the pharmaceutical industry.
Originally Published 2 months ago — by Axios
Medicare will now cover weight-loss drugs like Ozempic and Wegovy through a deal with Eli Lilly and Novo Nordisk, significantly reducing costs and expanding access for seniors and certain high-risk groups, starting with a pilot program in 2026.
Originally Published 2 months ago — by CNBC
President Trump announced deals with Eli Lilly and Novo Nordisk to significantly reduce the out-of-pocket costs of weight loss drugs, including GLP-1 injections like Wegovy and Zepbound, with prices potentially dropping to as low as $50 to $350 per month depending on coverage and dosage, expanding access through Medicare, Medicaid, and direct-to-consumer platforms.